The goal of the Penn lab is to better understand two oncogenic pathways that contribute to numerous human cancers of diverse origin, and then to exploit this knowledge to develop novel, effective inhibitors and/or treatment strategies. First, the aim is to inhibit MYC oncoprotein activity by driving MYC protein degradation and/or blocking essential post-translational modifications and protein interactors. Second, the aim is to maximize the anticancer efficacy of approved inhibitors of the metabolic mevalonate pathway, statins, which are presently used to control hypercholesterolemia. Thus, multiple new strategies are being used to improve cancer patient outcomes.
Linda J Z Penn, PhD
Senior Scientist, Princess Margaret Cancer Centre